Cargando…
Improvement of survival for non-small cell lung cancer over time
Non-small cell lung cancer (NSCLC) is the main histological subtype of lung cancer, which is the leading cause of cancer death. It is unclear whether the improved survival seen at high-volume centers applies to the general population and, more importantly, whether the improvement in lung cancer surv...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587133/ https://www.ncbi.nlm.nih.gov/pubmed/28919778 http://dx.doi.org/10.2147/OTT.S145036 |
_version_ | 1783261942424535040 |
---|---|
author | Xia, Wenjie Yu, Xinnian Mao, Qixing Xia, Wenying Wang, Anpeng Dong, Gaochao Chen, Bing Ma, Weidong Xu, Lin Jiang, Feng |
author_facet | Xia, Wenjie Yu, Xinnian Mao, Qixing Xia, Wenying Wang, Anpeng Dong, Gaochao Chen, Bing Ma, Weidong Xu, Lin Jiang, Feng |
author_sort | Xia, Wenjie |
collection | PubMed |
description | Non-small cell lung cancer (NSCLC) is the main histological subtype of lung cancer, which is the leading cause of cancer death. It is unclear whether the improved survival seen at high-volume centers applies to the general population and, more importantly, whether the improvement in lung cancer survival was just a consequence of improved screening work. Data from the Surveillance, Epidemiology, and End Results (SEER) registry was used to identify 405,580 patients with NSCLC diagnosed from 1988 to 2008. The patients were divided into four groups according to the year of diagnosis. Trends of clinical characteristics were analyzed to reflect the progress of screening work. Five-year relative survivals in various subgroups were compared. The results indicated that proportion of aged, advanced, and non-surgical patients increased, whereas patients with lymph node metastasis and high histology grade decreased. Improvements in all stages of NSCLC patients were demonstrated, with relatively more significant gains for patients with localized and regional disease. After potentially curative surgical resection, remarkable improvements were observed in both cohorts with time (surgical: 52.00%–63.00%; non-surgical: 6.10%–13.50%). Specifically, patients who underwent pneumonectomy, lobectomy/bilobectomy, and partial/wedge/segmental resection all presented better survival rates. Our SEER analysis demonstrated improvements among patients in all stages of NSCLC that were deemed attributable to improved therapy and medical care for NSCLC rather than improved screening work. |
format | Online Article Text |
id | pubmed-5587133 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-55871332017-09-15 Improvement of survival for non-small cell lung cancer over time Xia, Wenjie Yu, Xinnian Mao, Qixing Xia, Wenying Wang, Anpeng Dong, Gaochao Chen, Bing Ma, Weidong Xu, Lin Jiang, Feng Onco Targets Ther Original Research Non-small cell lung cancer (NSCLC) is the main histological subtype of lung cancer, which is the leading cause of cancer death. It is unclear whether the improved survival seen at high-volume centers applies to the general population and, more importantly, whether the improvement in lung cancer survival was just a consequence of improved screening work. Data from the Surveillance, Epidemiology, and End Results (SEER) registry was used to identify 405,580 patients with NSCLC diagnosed from 1988 to 2008. The patients were divided into four groups according to the year of diagnosis. Trends of clinical characteristics were analyzed to reflect the progress of screening work. Five-year relative survivals in various subgroups were compared. The results indicated that proportion of aged, advanced, and non-surgical patients increased, whereas patients with lymph node metastasis and high histology grade decreased. Improvements in all stages of NSCLC patients were demonstrated, with relatively more significant gains for patients with localized and regional disease. After potentially curative surgical resection, remarkable improvements were observed in both cohorts with time (surgical: 52.00%–63.00%; non-surgical: 6.10%–13.50%). Specifically, patients who underwent pneumonectomy, lobectomy/bilobectomy, and partial/wedge/segmental resection all presented better survival rates. Our SEER analysis demonstrated improvements among patients in all stages of NSCLC that were deemed attributable to improved therapy and medical care for NSCLC rather than improved screening work. Dove Medical Press 2017-08-29 /pmc/articles/PMC5587133/ /pubmed/28919778 http://dx.doi.org/10.2147/OTT.S145036 Text en © 2017 Xia et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Xia, Wenjie Yu, Xinnian Mao, Qixing Xia, Wenying Wang, Anpeng Dong, Gaochao Chen, Bing Ma, Weidong Xu, Lin Jiang, Feng Improvement of survival for non-small cell lung cancer over time |
title | Improvement of survival for non-small cell lung cancer over time |
title_full | Improvement of survival for non-small cell lung cancer over time |
title_fullStr | Improvement of survival for non-small cell lung cancer over time |
title_full_unstemmed | Improvement of survival for non-small cell lung cancer over time |
title_short | Improvement of survival for non-small cell lung cancer over time |
title_sort | improvement of survival for non-small cell lung cancer over time |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587133/ https://www.ncbi.nlm.nih.gov/pubmed/28919778 http://dx.doi.org/10.2147/OTT.S145036 |
work_keys_str_mv | AT xiawenjie improvementofsurvivalfornonsmallcelllungcancerovertime AT yuxinnian improvementofsurvivalfornonsmallcelllungcancerovertime AT maoqixing improvementofsurvivalfornonsmallcelllungcancerovertime AT xiawenying improvementofsurvivalfornonsmallcelllungcancerovertime AT wanganpeng improvementofsurvivalfornonsmallcelllungcancerovertime AT donggaochao improvementofsurvivalfornonsmallcelllungcancerovertime AT chenbing improvementofsurvivalfornonsmallcelllungcancerovertime AT maweidong improvementofsurvivalfornonsmallcelllungcancerovertime AT xulin improvementofsurvivalfornonsmallcelllungcancerovertime AT jiangfeng improvementofsurvivalfornonsmallcelllungcancerovertime |